Surgery Partners, Inc. (SGRY) Stock Price & Analysis

Surgery Partners, Inc. (SGRY) closed at USD 15.9 on Thursday, October 22, 2026, up 3.25% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 15.9; the Oct 22, 2026 session ranged USD 15.35–16 on volume of 2,906,280 shares. Market capitalization is —, with a 52-week range of USD 11.41–23.44 (NMS). Source: Nexqual, retrieved October 23, 2026 at 11:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SGRY.md

Key facts (SGRY)

• Last four reported quarters (through Jun 30, 2026): revenue $3.37B, net income -$88.6M (-2.6% margin), free cash flow $188M (SEC filings).
• 1 of 80 tracked superinvestors hold SGRY (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $144K; 0 by opportunistic insiders, 0 by routine insiders.
• Total return with dividends: 1Y -27.6% vs S&P 500 +14.9%; 5Y -63.5% vs S&P 500 +80.3%.
• Next earnings: 2026-11-09, EPS estimate USD 0.12, revenue estimate $796M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SGRY)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SGRY)

Superinvestors (SEC 13F-HR, Q2 2026) (SGRY)

1 of 80 tracked investors hold SGRY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider purchases (SEC Form 4, open-market, last ~7 months) (SGRY)

1 purchase, $144K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (SGRY)

Rating changes, last 120 days:

Total return (dividends reinvested) (SGRY)

SGRY revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

SGRY analyst estimates and revisions

SGRY options: expected move

Options price a move of about ±15.5% (±$2.40) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±8.5% on average.

30-day implied volatility 61.1% vs 61.7% realized over the last 30 trading days. Put/call ratio (volume) 0.03. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 11:23 UTC)

Technical Analysis (SGRY)

Nexqual's technical model rates SGRY "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 11:23 UTC.

Earnings (SGRY)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 11:23 UTC.

Financials & Fundamentals (SGRY)

Source: Nexqual, October 23, 2026 at 11:23 UTC.

Ownership (SGRY)

Source: Nexqual, October 23, 2026 at 11:23 UTC.

From Surgery Partners, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• Patient services provided in our ASCs and surgical hospitals (collectively, "surgical facilities" or "facilities") generated approximately $3.2 billion in revenue during 2025.
• We are subject to the Medicare Patient and Program Protection Act of 1987, as amended by the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), including the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act"), which was enacted as part of The American Recovery and Reinvestment Act of 2009.
• Our differentiated operating model employs a multifaceted strategy to grow revenue, earnings and cash flow.

Partnerships

• The HITECH Act strengthened the requirements of the HIPAA privacy and security regulations and significantly increased the penalties for violations by introducing a tiered penalty system, with penalties of up to $50,000 per violation with a maximum civil penalty of $1.5 million in a calendar year for violations of the same requirement.
• Violations of the Anti-Kickback Statute are criminal offenses punishable by imprisonment and fines of up to $100,000 for each violation.

Legal & Regulatory Risks (Item 1A, quoted)

• We cannot predict the effect that changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
• Our surgical facilities do not satisfy the requirements for any of the safe harbors under the federal Anti-Kickback Statute. If a federal or state agency asserts a different position or enacts new laws in this regard, we could be subject to criminal and civil penalties, loss of licenses and exclusion from governmental programs, which may result in a substantial loss of revenue.
• Failure to comply with Medicare's conditions for coverage and conditions of participation may result in loss of program payment or other governmental sanctions.
• Our facilities could face decreased Medicare payments if they fail to report and meet various quality metrics.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt